Kyntra Bio Inc KYNB

$3.73 +0.07 (1.91%)

Valuation

Market cap
14,820,000
Revenue TTM
$6,440,000
Net income TTM
$183,450,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
2,848.60%
Debt to equity
0.00

Trading

Volume
14,500
Avg volume
24,378
Day's range
$3.61 – $3.88
Shares out
4,049,000
Stochastic %K
10%
Beta
1.08
Analysts
Moderate Buy
Price target
$36.80

Price

Company profile

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase...

Show more

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 978 1200
Website
https://www.kyntrabio.com
Address
350 Bay Street, Suite 100 #6009, San Francisco, United States

Latest news

Stocktwits

MaxMiamiFl Nov 5, 8:25 PM
$KYNB The Nasdaq was down approximately 5.1% today
0 replies
ikkydiphoenix Nov 5, 7:42 PM
$KYNB i suppose even the CEO forgot the existence of this company
1 replies
MaxMiamiFl Nov 5, 3:51 PM
$KYNB
0 replies
Hanse2014 Nov 2, 7:02 PM
$KYNB Hopegully good news im Q4
1 replies
Estimize Nov 2, 3:48 PM
Wall St is expecting -3.55 EPS for $KYNB Q3 [Reporting 11/09 AMC] http://www.estimize.com/intro/kynb?chart=historical&metric_name=eps&utm_c
0 replies
Itsybitsybeanbag Oct 26, 5:01 PM
$KYNB POS
3 replies
MaxMiamiFl Oct 23, 7:48 PM
$KYNB 13% plus...down today, Insanity.
1 replies
MaxMiamiFl Oct 21, 3:26 PM
$KYNB 25% down since they elected this clown
0 replies